Phase 1 Oesophageal Cancer Trial, Recruiting NCT07334119 Sponsor: Myeloid Therapeutics Condition: Oesophageal Cancer
Back to Oesophageal Cancer

Phase 1 Oesophageal Cancer Trial, Recruiting

NCT07334119
Recruiting Phase 1 🇦🇺 Australian site

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People aged 18 years or older
  • People who have been diagnosed with metastatic or advanced epithelial cancer (a type of cancer affecting the lining of organs or tissues) that has been confirmed by laboratory testing and shows a protein called HER2 on the cancer cells
  • People whose cancer has at least one measurable area that can be tracked using standard imaging measurements
  • People who are relatively well and able to carry out daily activities, rated as 0 or 1 on a standard medical scale of physical wellbeing
  • People whose organs (such as liver, kidneys, and heart) are functioning at an adequate level

Who may not be able to join:

  • People who have active cancer that has spread to the brain or the lining around the brain or spinal cord
  • People who have any current acute illness, including a fever
  • People who have a history of heart failure with symptoms
  • People who have previously had lung inflammation or scarring (not caused by infection) that needed steroid treatment, or who currently have this condition
  • People who have uncontrolled build-up of fluid around the lungs, around the heart, or in the abdomen
  • People who have an active autoimmune disease (where the immune system attacks the body) that is unrelated to previous cancer treatment and has required ongoing medical treatment within the last year

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 21 July 2026
Phase 1: approximately ~10% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Matthew Maurer, MD, Myeloid Therapeutics

Phone: +61731376255

Australian sites

The Kinghorn Cancer Centre, Darlinghurst, New South Wales
+61393555655
Scientia Clinical Research Ltd, Randwick, New South Wales
Calvary Mater Newcastle, Waratah, New South Wales
+61240143282
Icon Cancer Centre South Brisbane, South Brisbane, Queensland
+61737374500
Cancer Research SA Pty Ltd, Adelaide, South Australia
+61883592565
Cabrini Health, Melbourne, Victoria
+61395083437
Linear Clinical Research, Nedlands, Western Australia
+61863825100

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 1
Sponsor
Myeloid Therapeutics
Registry
ClinicalTrials.gov
Start date
25 November 2025
Est. completion
31 January 2027

Where this trial is recruiting

🇦🇺 Australia

7 site(s) in Australia. Confirm current status and contact details directly with the trial site.

Primary endpoints

Type, incidence and severity of Adverse Events; Number of Participants With Change From Baseline in Vital Signs (Composite Safety Outcome); Number of Participants With Abnormal Clinical Laboratory Parameters (Composite Safety Outcome); Number of Participants With Change From Baseline in ECG Parameters (Composite Safety Outcome); Maximum Tolerated Dose (MTD); Optimal Biological Dose (OBD)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 21 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov